1. Cancer statistics;Siegel;CA Cancer J Clin,2012
2. Phase III trial (E5592) comparing cisplatin plus etoposide with cisplatin plus paclitaxel at two dose levels for treatment of advanced non-small-cell lung cancer. Eastern Cooperative Oncology Group;Johnson;J Natl Cancer Inst Monogr,1995
3. Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway;Pasquier;Mol Cancer Ther,2004
4. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med,2006
5. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors;Sweeney;Cancer Res,2001